SLG
TRIL

Stanley-Laman Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Stanley-Laman Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-139,403
Closed -$809K – 308
2018
Q3 		$809K Buy
139,403
+2,312
+2% +$13K 0.2% 154
2018
Q2 		$823K Buy
137,091
+28,907
+27% +$184K 0.18% 163
2018
Q1 		$779K Buy
+108,184
New +$820K 0.18% 165

Other funds holding TRIL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Stanley-Laman Group's TRIL Position: Q4 2018 in Review

Stanley-Laman Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2018, closing a stake of 139,403 shares — an estimated $809K sold.

Stanley-Laman Group first reported a position in TRIL in Q1 2018 and held it in 3 quarters. The position peaked at $823K in Q2 2018. 23 funds tracked by Wall St. Rank hold TRIL as of Q4 2018.

  • Stanley-Laman Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 139,403 Trillium Therapeutics Inc. shares in Q4 2018, an estimated $809K.
  • Stanley-Laman Group first reported a position in Trillium Therapeutics Inc. in Q1 2018 and held it in 3 quarters.
  • Stanley-Laman Group's Trillium Therapeutics Inc. position peaked at $823K in Q2 2018.
  • 23 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2018.

Based on Stanley-Laman Group's 13F filing for Q4 2018, filed 7 Feb 2019.